Trump Announces Deals to Lower Weight-Loss Drug Prices

On November 6, 2025, President Trump announced agreements with drugmakers Eli Lilly and Novo Nordisk to lower prices on GLP-1 weight-loss and diabetes drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound. Under the deals, eligible Medicare and Medicaid patients would pay around $245 per month, while consumers using the planned direct-to-consumer "TrumpRx" website would pay roughly $350 for injectables and $149 for an initial oral GLP-1 dose, compared to list prices as high as $1,350 monthly.

The agreements rely on voluntary industry commitments rather than legislation, with new pricing set to begin in January 2026 and Medicare coverage expected around mid-2026. Officials framed it as proof that executive pressure can achieve results Congress has not delivered.

Health policy analysts noted the details remained murky, including exactly who qualifies and how enforceable the voluntary commitments are, since the arrangement bypasses statutory drug-pricing reform and depends on continued cooperation from the manufacturers.